Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.

导出 LinkOut

翻译打印收藏纠错

第一作者： Renu,Gahlaut

第一单位： Histopathology, St James's Institute for Oncology, St James's University Hospital, Leeds, UK.

作者： Renu,Gahlaut ^[1] ; Aneliese,Bennett ^[1] ; Hiba,Fatayer ^[2] ; Barbara J,Dall ^[3] ; Nisha,Sharma ^[3] ; Galina,Velikova ^[4] ; Tim,Perren ^[5] ; David,Dodwell ^[4] ; Mark,Lansdown ^[2] ; Abeer M,Shaaban ^[6]

作者单位： Histopathology, St James's Institute for Oncology, St James's University Hospital, Leeds, UK. ^[1] Breast Surgery, St James's Institute for Oncology, St James's University Hospital, Leeds, UK. ^[2] Imaging and Breast Screening, St James's University Hospital, Leeds, UK. ^[3] St James's Institute for Oncology, St James's University Hospital, Leeds, UK. ^[4] St James's Institute for Oncology, St James's University Hospital, Leeds, UK; Leeds Institute of Cancer Medicine and Pathology, St James's Institute of Oncology, St James's University Hospital, Leeds, LS9 7TF, UK. ^[5] Pathology, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre and the University of Birmingham, Birmingham, UK; University of Tanta, Egypt. Electronic address: abeer.shaaban@uhb.nhs.uk. ^[6]

关键词 Breast cancer HER2 Neoadjuvant chemotherapy Oestrogen receptor Progesterone receptor